Hodgkin Lymphoma Treatment Market Size, Share & Industry Analysis, By Type (Classical Hodgkin Lymphoma , Nodular Lymphocyte-Predominant Hodgkin Lymphoma) , By Treatment (Chemotherapy, Radiation Therapy, Drugs, Others), By End-Users (Hospitals, Clinics, Research Centres) And Regional Forecast, 2024-2032

Hodgkin’s lymphoma is also called Hodgkin disease (HD), and Hodgkin lymphoma, mainly occurs due to the infection by Epstein–Barr virus (EBV). HD is a cancer of the lymphatic system in which cancer initiates from a specific type of white blood cells called lymphocytes. It exists in two forms, first and most common is classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. In people with HD, lymphocytes grow abnormally and spread beyond the lymphatic system. As the disease progresses, it makes it more difficult for the body to fight infections. However, advances in diagnosis and treatment of HD have helped give people a chance for a full recovery in most cases. The course of the medical condition continues to improve the people with HD. The possibility of full recovery from HD is expected to drive the market.

An increase in prevalence and incidences of infection by EBV are expected to drive the market. About half of cases of Hodgkin lymphoma occur due to the infection by EBV and these are generally the classic form. According to Bio MedCentral (BMC) 2019, the EBV is estimated to be positive in more than 90% of the world’s populations. Moreover, this virus has been connected to a wide range of malignancies, such as HD, post-transplant lymphoproliferative diseases (PTLDs), gastric carcinoma, and nasopharyngeal carcinoma (NPC). Moreover, other risk factors like a family history of the HD and having HIV/AIDS are further expected to drive the market. According to the Joint United Nations Program on HIV and AIDS (UNAIDS) 2019, globally around 40 million people were estimated to have HIV.

However, side effects from cancer treatment with radiation therapy and/ or chemotherapy for HD may increase the risk of second cancers, and other health problems such as infertility, heart diseases, lung diseases, etc. may restrain the market growth.

Key Market Driver -

increasing prevalence and incidences of infection by EBV and HIV are projected to boost the market

Key Market Restraint -

the side effects like risk of second cancers from of treatment is likely to hinder the market growth

Market Segmentation:

The global hodgkin's lymphoma treatment market can be segmented on the basis of type, treatment, end-user, and region. Based on the type, the market can be segmented into classical hodgkin lymphoma and nodular lymphocyte-predominant hodgkin lymphoma. Based on the treatment, the market can be segmented into chemotherapy, radiation therapy, drugs and others. Based on end-users the market can be segmented into hospitals, clinics, and research centers.

Geographically, hodgkin’s lymphoma treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Key Players Covered:

The major companies in the global hodgkin’s lymphoma treatment report includes Abbott, CELGENE CORPORATION A BRISTOL-MYERS SQUIBB COMPANY, Merck Sharp & Dohme Corp., Seattle Genetics, Inc., Millennium Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited. Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Eli Lilly & Company and other prominent players.

Key Insights:

• Key Industry Developments - Mergers, Acquisitions and Partnerships


• Recent Hodgkin’s lymphoma treatment Research & Development Activities


• Pipeline Analysis of New Drug


• Prevalence of Hodgkin’s Lymphoma and AIDS

Regional Analysis:

Geographically, the global hodgkin’s lymphoma treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to hold the largest share in hodgkin's lymphoma treatment market and is anticipated to continue this trend during the forecast period. This growth can be attributed to the well-established healthcare infrastructure, presence of key players, high R&D expenditure, and availability of novel drugs. The market in Europe is likely to have substantial market growth throughout the forecast period owing to the enormous healthcare expenditure and advantageous health cover policies. However, Asia Pacific is estimated to witness significant growth during the forecast period due to the increase in healthcare expenditure, high unmet clinical needs, increase in awareness about treatment options, and availability of effective treatment in emerging countries such as India, China & South Korea.

To gain extensive insights into the market, Request for Customization

Segmentation

Hodgkin’s Lymphoma Treatment Market Industry Developments

• In June 2018 – The Janssen Global Services, pharmaceutical company of Johnson & Johnson Services, Inc. announced results from a pre-planned interim analysis of the Phase 3 iNNOVATE study evaluating the investigational use of IMBRUVICA® (ibrutinib) in combination with rituximab in relapsed/refractory and treatment-naïve patients with Waldenström’s macroglobulinemia (WM) a form of lymphoma.


• In March 2018, The drug, Adcetris (brentuximab vedotin), was approved for use in combination with a chemotherapy regimen commonly known as AVD by FDI. Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited had collaborated to sell and market this drug.